FDA review of Alzheimer’s drugs
Approximately 60 percent of new drug applications for Alzheimer's therapies are approved by FDA in the first cycle, compared to 96 percent for HIV/AIDS drugs and 94 percent for selected cancer therapies, according to a report by Avalere Health. The consulting firm evaluated review times for five Alzheimer's therapies, 26 HIV/AIDS drugs, and 18 cancer treatments. "We found that the FDA met PDUFA review timelines for all drug categories; there was no evidence of a slower or delayed FDA review time for Alzheimer's," Avalere reports. However, HIV/AIDS and cancer drugs were more successful than Alzheimer's drugs at obtaining priority review and approval in the first cycle. The study was sponsored by Wyeth, which has 11 candidates under development to treat Alzheimer's disease, including bapinezumab, slated to enter Phase III in the second half of the year. Bapinezumab, codeveloped by Elan, has been granted fast track designation by FDA...
You may also be interested in...
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.